businessMar 31, 20267:04failed
2353: Poolbeg Pharma Secures First Oncology Patent for POLB 001
About this episode
Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.
Get every episode summarized
Each time The Vox Markets Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Vox Markets Podcast
2369: Poolbeg hits significant milestone with POLB 001
The Vox Markets Podcast
Apr 15, 20266:18failed
2368: hVIVO FY25 Results: Growth, Acquisitions and What Comes Next in 2026
The Vox Markets Podcast
Apr 15, 20268:41failed
2367: Quantum Data Energy CEO on Q1 Progress
The Vox Markets Podcast
Apr 15, 202611:52failed
2366: Chancery Royalty gets set for US$7,000 gold
The Vox Markets Podcast
Apr 14, 202613:58failed